靶向外显子组组合的性能并不都相同，在某些情况下可能会遗漏对实验至关重要的数据。本交互式技术说明提供了 Twist Exome 2.0 组合与其他供应商提供的 4 种市售组合的比较数据。

With the rapid growth and availability of next-generation sequencing has come the need for efficient target enrichment solutions across multiple applications.  Targeted sequencing maximizes testing resources by selectively narrowing sequencing output to only your regions of interest, enabling increased depth per sample and limiting cost.  As we move into the genomics era, flexible and scalable library preparation and target enrichment workflows are critical to meet the expanding diagnostic landscape. Twist continues to provide innovative NGS solutions to empower researchers; from assay development tools such as our cfDNA Pan-Cancer Reference Standards to rare variant allele detection with our Unique Molecular Identifiers (UMI).  Comprehensive identification and study of methylation biomarkers can be performed with Twist’s highly efficient methylation capture workflow.  In order to support the growing clinically relevant variants for developing NGS-based assays, Twist MRD Twist MRD Rapid 500 Panels provide researchers with customized NGS tests in as little as six business days.     In this workshop from AMP 2022, Shawn Gorda, Senior Staff Product Manager at Twist Biosciences, showcases Twist’s diverse selection of target enrichment and library preparation pipelines for NGS. He is then joined by Jonathan Keats, Assistant Professor in the Integrated Cancer Genomics Division at the Translational Genomics Research Institute (TGen), who will demonstrate how he used Twist’s UMIs and Library Preparation EF 2.0 to identify novel genetic biomarkers in multiple myeloma patients.   仅供研究使用，不得用于诊断程序。

Twist 人类样本 ID 试剂盒提供了一种简单的多重 PCR 方法，可确保从基因组学检测的早期步骤便可开始进行样本识别和追踪。由于测序工作流程高度复杂，因此不可避免地会出现样本混淆的情况，这可能会需要对关键样本数据进行成本高昂的重新测试，或者造成错误的解读。凭借其可直接从血液内提取样本以及强大的鉴别能力，Twist 人类样本 ID 试剂盒可将正确的结果与相应的样本进行可靠地匹配。